Journals / Veterinary Sciences and Practices / 2020 / Cilt: 15 Sayı: 1

Protective Effect of Silymarin on Diethylnitrosamine Induced Hepatocellular Carcinoma Model in Wistar Rats; Cancer Patterns and Cytological Variants

Wistar Ratlarında Dietilnitrozamin Uygulanarak Oluşturulan Hepatoselüler Karsinom Modelinde Silimarin’in Koruyucu Etkisi; Kanser Paternleri ve Sitolojik Varyantlar

Pages
43–50
Publication Date
2020-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We observed that Hepatocellular carcinoma occurred in DEN and DEN + Silymarin groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, the protective effect of silymarin was investigated with histopathological methods in terms of cancer patterns and cytological variants in the hepatocellular carcinoma model created by applying diethylnitrosamine experimentally in rats.
📊
Key Findings & Data:For this purpose, the rats were randomly divided into 5 groups.
💡
Conclusion & Impact:We observed that Hepatocellular carcinoma occurred in DEN and DEN + Silymarin groups.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Dietilnitrozamin · Hepatoselüler Karsinom · Paternler

Abstract

In this study, the protective effect of silymarin was investigated with histopathological methods in terms of cancer patterns and cytological variants in the hepatocellular carcinoma model created by applying diethylnitrosamine experimentally in rats. For this purpose, the rats were randomly divided into 5 groups. The rats in the control group were fed pellet feed and drinking water for 20 weeks. Animals in Sham group were administered with propylene glycol dissolved in 0.9% NaCl intraperitoneally 3 times a week for 20 weeks. Animals in DEN group administered DEN at a dose of 50 mg/kg once a week for 20 weeks. The rats in the DEN +Silymarin group were Silymarin intraperitoneally administered for 21 weeks 3 times a week at a dose of 100 mg/kg, starting 1 week prior to the administration of DEN. Silymarin was administered to rats in the group of Silymarin 3 times a week intraperitoneally for 20 weeks at a dose of 100 mg/kg. At the end of the study, systemic necropsy of the animals was performed and liver tissue samples were taken. After routine tissue procedures, sections were examined under the light microscope. We observed that Hepatocellular carcinoma occurred in DEN and DEN + Silymarin groups.

Özet

Bu çalışmada, ratlarda deneysel olarak Dietilnitrozamin uygulanarak oluşturulan Hepatoselüler karsinom modelinde Silimarin’in koruyucu etkisi kanser paternleri ve sitolojik varyantlar açısından histopatolojik metodlarla araştırılmıştır. Bu amaçla ratlar 5 gruba ayrıldı. Kontrol grubundaki ratlara 20 hafta boyunca pelet yem ve içme suyu verildi. Sham grubundaki hayvanlara %0.9 NaCl içerisinde çözdürülmüş propilen glikol intraperitoneal yolla haftada 3 kez olmak üzere 20 hafta boyunca verildi. DEN grubundaki hayvanlara 50 mg/kg dozunda haftada 1 kez olmak üzere 20 hafta boyunca DEN uygulaması yapıldı. DEN+Silimarin grubundaki ratlara DEN uygulamasından 1 hafta önce başlayacak şekilde 100 mg/kg dozunda haftada 3 kez olmak üzere 21 hafta boyunca intraperitoneal yolla Silimarin uygulandı. Silimarin grubundaki ratlara 100 mg/kg dozunda 20 hafta boyunca intraperitoneal yolla haftada 3 kez olmak üzere Silimarin uygulandı. Çalışmanın sonunda, hayvanların sistemik nekropsisi yapıldı ve karaciğer doku örnekleri alındı. Rutin doku takip işlemlerinden sonra kesitler ışık mikroskobu altında değerlendirildi. DEN ve DEN+Silimarin gruplarında Hepatoselüler karsinom oluştuğunu gözlemledik

🔖

Cite This Article

KARAKURT, E., DAĞ, S. (2020). Protective Effect of Silymarin on Diethylnitrosamine Induced Hepatocellular Carcinoma Model in Wistar Rats; Cancer Patterns and Cytological Variants. Veterinary Sciences and Practices, Cilt: 15 Sayı: 1, 43–50. https://ajindex.com/articles/917552

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Medhat A., Mansour S., El-Sonbaty S., Kandil E., Mahmoud M., 2017. Evaluation of the antitumor activity of platinum nanoparticles in the treatment of hepatocellular carcinoma induced in rats. Tumour Biol, 39,1-10
  2. Elsayed MM., Mostafa ME., Alaaeldin E., Sarhan HA., Shaykoon MS., Allam S., Ahmed AR., Elsadek BE., 2019. Design and characterisation of novel sorafenib-loaded carbon nanotubes with distinct tumour-suppressive activity in hepatocellular carcinoma. Int J Nanomedicine, 14, 8445-8467
  3. Livingstone MC., Johnson NM., Roebuck BD., Kensler TW., Groopman JD., 2019. Serum miR-182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats. Mol Carcinog, 58, 2017-2025
  4. Salama YA., El-Karef A., El Gayyar AM., Abdel-Rahman N., 2019. Beyond its antioxidant properties: Quercetin targets multiple signalling pathways in hepatocellular carcinoma in rats. Life Sci, 236, 116933
  5. Subramaniam N., Kannan PKA., Thiruvengadam D., 2019. Hepatoprotective effect of boldine against diethylnitrosamine-induced hepatocarcinogenesis in wistar rats. J Biochem Mol Toxicol, 33, e22404
  6. Rawla P., Sunkara T., Muralidharan P., Raj JP., 2018. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn), 22, 141-150
  7. Fahmi A., Hassanen N., Abdur-Rahman M., Shams-Eldin E., 2019. Phytochemicals, antioxidant activity and hepatoprotective effect of ginger (Zingiber officinale) on diethylnitrosamine toxicity in rats. Biomarkers, 24, 436-447
  8. Moawed FS., El-Sonbaty SM., Mansour SZ., 2019. Gallium nanoparticles along with low-dose gamma radiation modulate TGF-β/MMP-9 expression in hepatocellular carcinogenesis in rats. Tumour Biol, 41, 1010428319834856
  9. Bosch-Barrera J., Menendez JA., 2015. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev, 41, 540-546
  10. Anwar S., Madkor HR., Ahmed N., Wagih ME., 2018. In vivo anticlastogenic effect of silymarin from milk thistle Silybum marianum L. Indian J Pharmacol, 50, 108-115
  11. Cullen JM., 2017. Tumors of the Liver and Gallbladder. In ‘’Tumors in Domestic Animals’’, Ed., DJ Meuten, 5th ed., 602-622, Wiley Blackwell, Iowa
  12. Geller SA., Petrowic LM., 2009. Primary and Metastatic Malignant Tumors of the Liver. In ‘’Biopsy Interpretation of the Liver’’, Ed., SA Geller, LM Petrowic, 2nd ed., 319-368, Lippincott Williams & Wilkins, Philadelphia
  13. Washington K., Harris E., 2010. Masses of the Liver. In ‘’Sternbe